Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides effective protection against respiratory syncytial virus-related lower respiratory tract disease (RSV-LRTD) in adults aged 60 and older across three consecutive RSV seasons. Cumulative efficacy reached 62.9%, with protection observed against both RSV A and RSV B subtypes.
Single-dose vaccine demonstrates sustained efficacy against RSV-related lower respiratory tract disease in older adults
